6533b861fe1ef96bd12c45f2
RESEARCH PRODUCT
Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children.
Peter P. TothRizzo ManfrediDragana NikolicAndreea CorinaLubna Hammadsubject
medicine.medical_specialtyAdolescentFamilial hypercholesterolemiastatins03 medical and health sciences0302 clinical medicineEzetimibechildrenmedicinePharmacology (medical)Risk factorIntensive care medicinePharmacologyfamilial hypercholesterolemiaAtherosclerotic cardiovascular diseasebusiness.industryfungidyslipidemiafood and beveragesGeneral Medicinemedicine.diseaseYoung age030220 oncology & carcinogenesisbusinessDeveloped country030217 neurology & neurosurgeryDyslipidemiamedicine.drugezetimibedescription
Dyslipdiemia can manifest at a young age, and it is a risk factor for atherosclerotic cardiovascular disease (ASCVD), the principal cause of mortality in developed nations. Therefore, treating it a...
year | journal | country | edition | language |
---|---|---|---|---|
2018-12-07 | Expert opinion on pharmacotherapy |